INTRODUCTION
Tuberculosis (TB) remains an important cause of morbidity and mortality worldwide, with 8.7 million new infections and 1.4 million deaths annually and in view of the spread of drugresistant organisms, new measures to contain the disease are urgently needed. In this light, the lack of efficacy of the recombinant vaccinia virus booster vaccine, MVA85A, in a recent phase IIB trial in infants is a significant setback to TB vaccine research, 1,2 although much has been learnt about the conduct of a proof-of-concept efficacy trial in a high TB burden setting. 3 Furthermore, although there are currently many other vaccine candidates in clinical trials, most of which induce similar immune responses to MVA85A, because of the lack of a protective immune correlate there is no certainty that any of these parenteral vaccines will be effective. 4 Therefore, continuing development of new strategies and a better understanding of the nature of protective immunity remain important goals for TB research. Here we review the nature of protective immunity to Mycobacterium tuberculosis (Mtb) and discuss a potentially novel strategy for improving immunization against TB, the harnessing of local lung immunity as well as systemic immunity.
DELAYED INITIATION OF THE IMMUNE RESPONSE TO MTB
Few parenteral subunit vaccines when used alone show greater protective efficacy than Bacille Calmette Guerin (BCG) in animal models and even fewer provide a convincing increase in protection over BCG when used in prime/boost regimes. 4 Furthermore, there is no correlation between the magnitude of peripheral blood mononuclear cell immune responses and protection. Thus, for example, a single parenteral boost with MVA85A after BCG priming is highly immunogenic in animals [5] [6] [7] [8] [9] and humans. 2, 10 However, although in two of these studies, in cows 7 and primates, 8 there is a trend toward improved protection in MVA85A boosted animals compared with BCG alone, the difference does not reach statistical significance, whereas in mice 5 and guinea pigs 6 there is no trend toward improved protection and in a second primate experiment, BCG primed MVA85A boosted monkeys did not differ from naive, unimmunized animals. 9 Parenteral vaccine regimes that do induce improved protection over BCG alone frequently utilize multiple immunizations, which induces entry of cells into non-lymphoid tissues. 11, 12 This suggests that protection induced by effective parenteral regimes may depend not only on the quality of the response [13] [14] [15] [16] but also the migratory properties of the antigen-specific cells and their role at the site of entry of Mtb in the lungs.
On the basis of the development of skin test reactivity, a measurable adaptive immune response to Mtb takes 6 weeks after exposure or infection to emerge (reviewed by Ernst 17 ). In mice too, the immune response to mycobacteria introduced into the lungs is delayed. This may be because Mtb deploys immune evasion strategies or because the initial exposure is to a low dose of organisms. 18 Whatever the reason, it has been shown in mice that it is 8-10 days after infection before activated T cells can be detected in the draining mediastinal nodes and 12-14 days before they can be detected in the lungs. [19] [20] [21] Until this time, after an initial lag phase, Mtb grows logarithmically, but the appearance of T cells in the lungs correlates with inhibition of growth, indicating their importance in controlling infection. Remarkably, in mice immunized parenterally with protective vaccines, including BCG, the kinetics of Mtb growth are identical up to B12 days, although the mycobacterial load then stabilizes at a lower level than in naive animals 19, 20, 22, 23 ( Figure 1 ). Interestingly, in mice immunized parenterally with BCG, experiments using fingolimod, which inhibits egress of cells from lymph nodes, suggest that containment of challenge mycobacteria may not be due to an influx of cells from the periphery but rather to expansion of T cells already present in lung tissue. 24 Irrespective of the origin of cells mediating immunity after parenteral immunization, it appears that in the mouse, systemic immunity, although it may confer a degree of containment, does not prevent establishment of infection and allows Mtb to grow unchecked for 410 days. There is therefore a period after lung infection, which is affected minimally or inefficiently by parenteral immunization (Figure 1) . This period presents a challenge, or alternatively a window of opportunity, for vaccine strategies. Control of the early (first 10 days) phase of Mtb growth is likely to require local lung immune responses and therefore a better understanding of mucosal immunity will be needed in order to design effective mucosal vaccines.
LOCAL IMMUNITY TO MTB Tissue-resident T cells
In recent years, it has become clear that a large proportion of immune cells reside outside lymphoid organs and that tissueresident populations of lymphocytes are present in most organs. 25 In mice, it has been demonstrated for acute infections, such as influenza, Sendai virus or respiratory syncytial virus, that lung-resident T memory cells (T RM ) with specialized phenotypic and functional properties, 26 have an important role in protection against challenge, whereas T-cell memory detected in blood or lymphoid organs does not correlate well with protection. 27, 28 Direct proof that T RM are crucial for protective immunity in humans is more difficult to obtain. However, human lung-resident T cells differ in many respects from those present in peripheral blood and are enriched for memory cells able to respond to common respiratory pathogens such as influenza virus. 29 Furthermore, bronchoalveolar lavage (BAL) samples of purified protein derivative (PPD) skin test positive humans, with presumed latent TB infection, also contain PPD-reactive memory T cells. 30 
Upper and lower respiratory tract immunity
In the mouse, T cells responsible for immunity against respiratory virus infections are most effectively induced by intranasal immunization, with an inoculum volume that induces both upper and lower respiratory tract (URT and LRT) cellular immunity. 27 However, URT and LRT immunity are at least partially separable in mice, as deliberate immunization of the URT only, although it induces a nasal-associated lymphoid tissue response, does not induce LRT T RM . Furthermore, only LRT immunization generating LRT T RM , is protective against Mtb challenge. 31 Similarly, in macaques immunization with a 4 mm particle size aerosol, which delivers antigen to the LRT, was shown to induce much greater lung immune responses than intranasal immunization, suggesting that in this species, as in mice, URT and LRT immune responses are distinct. 32 It is not known how closely humans approximate to primates in this regard, as a human common respiratory tract mucosal system has been proposed, 33, 34 but its existence will only be established by systematic comparison of immune responses in the URT and LRT after deliberate immunization by one or the other route.
Lung immunity to Mtb, the mouse model LRT immunization against Mtb has been intensively investigated in mice. Thus, for example, LRT immunization with recombinant adenoviruses expressing Mtb antigen 85A (Ad85A) can generate protection equivalent to parenteral BCG and can also boost protection after parenteral BCG priming. [35] [36] [37] Boosting with MVA85A intranasally, albeit after intranasal priming with BCG, also significantly improves protection compared with BCG alone. 38 Kinetic studies of Mtb growth in the lungs of mice immunized with Ad85A provide an explanation for the efficacy of this route of immunization. Thus, Mtb growth is inhibited immediately after challenge in immunized mice and although after B1 week Mtb escapes and grows logarithmically, the mycobacterial load stabilizes at a Figure 1 Schematic of Mycobacterium tuberculosis (Mtb) growth after challenge in mice. Un-immunized mice show an initial lag followed by logarithmic growth in colony forming units (CFU) and a plateau when a primary response to Mtb occurs. Mice immunized parenterally show identical kinetics of Mtb growth until B14 days when further growth is inhibited (late phase immunity), while mucosal immunization inhibits Mtb growth early after challenge (early phase immunity), followed by logarithmic growth and eventual containment. Simultaneous immunization by both routes leads to inhibition of Mtb growth in both early and late phases of infection. The schematic is based on previously published data.
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MucosalImmunology | VOLUME 7 NUMBER 1 | JANUARY 2014 lower level than in naive mice 39 ( Figure 1) . Similarly, after respiratory tract or parenteral immunization with BCG or recombinant Mtb antigens, early inhibition of growth of Mtb was demonstrated only in LRT immunized mice. 22 Investigation of the location of antigen-specific cells after LRT immunization has shown that antigen-specific T cells are found in both lung interstitial tissue and at a high frequency in BAL, whereas in contrast they are not found in BAL after similar parenteral immunization, although they may be present in lung tissue. 36, 37, 40, 41 Analysis of the response to BCG, recombinant Ad85A or recombinant Mtb antigens, suggests that both CD8 T cells, predominantly induced by Ad85A, or CD4 T cells induced by BCG or recombinant Mtb antigens, can mediate early inhibition of Mtb growth after challenge. 22 The efficacy of lungresident CD8 T cells in protection has been highlighted by antibody depletion and cell transfer experiments. 41, 42 These data indicate that LRT immunization induces an activated, antigendependent, dividing population of lung T cells located at the site of entry of inhaled mycobacteria, which is able to inhibit the growth of mycobacteria early after Mtb infection.
As well as inducing BAL antigen-specific cells, LRT immunization can generate inducible bronchus-associated lymphoid tissue. 43, 44 This has an important role in the immune response to many respiratory infections and recent experiments with the mucosal adjuvant Escherichia coli holotoxin LT-IIb and ESAT6 peptide antigen, show that induction of inducible bronchus-associated lymphoid tissue also contributes to protection against Mtb.
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Protection against Mtb challenge is maintained for 46 months after LRT immunization with Ad85A and is associated with the continued presence of antigen-specific cells in the lungs, including the BAL. Furthermore, this population retains a highly activated phenotype and the cells continue to proliferate. 39, 42 Proliferation is antigen dependent, indicating that antigen is retained within the lung, and the population is largely self-maintaining with little contribution from cells entering the lungs from the periphery. 39, 42 However, additional antigen-specific cells can be recruited if antigen or inflammatory stimuli are introduced into the lungs. 41, 46 Lung immunity in bovines, non-human primates and humans
In contacts of active TB patients and those with paucibacillary pulmonary disease, Mtb antigen-specific T-cell responses are detected in the BAL but not in the peripheral blood, suggesting that local lung immune responses may have a vital role in protective immunity early after Mtb exposure. 47 Interestingly, in active TB patients with higher bacterial loads, antigenspecific CD3 þ T-cell responses are detected in both the BAL and blood, although responses are generally higher in the BAL near the site of infection, than the peripheral blood. 48, 49 These data are correlative but the potential of mucosal memory T cells, induced through infection or vaccination, to respond to antigen re-exposure has been elegantly demonstrated by intrapulmonary challenge with PPD in healthy adults. Rapid expansion of antigen-specific T cells was detected in the BAL 48 h post-challenge only in individuals with a positive skin test to PPD. Thus, prior priming generated a memory pool capable of rapid response on subsequent antigenic re-exposure. 30 However, there is little data on immune responses in the lungs following vaccination.
Non-human primate studies have demonstrated the efficacy of immunization with parenteral BCG against pulmonary Mtb challenge, [50] [51] [52] which may be dependent on antigen-specific CD8 þ T cells. 51 Pulmonary administration of BCG induces higher frequencies of mucosal ab and gd T cells compared with systemic administration, which induces stronger peripheral responses 53 and remarkably, studies in 1973 in non-human primates comparing different routes of administration demonstrated improved BCG-induced protection against aerosol Mtb challenge in animals receiving aerosolized compared with parenteral BCG. 54 However, limited data suggest that the outcome of immunization by the respiratory route may be influenced by the host species and vaccine vector, as well as the exact methodology used, for example, aerosol vs. endobronchial immunization. Non-human primates immunized by aerosol with an adenoviral vector maintained a high frequency of antigen-specific T cells in BAL for many months, whereas the response of peripheral blood mononuclear cell was transient. 32 However, in macaques immunized with MVA85A there was a much less clear cut difference between lung or peripheral immune responses following aerosol or intradermal immunization. 55 In bovines, boosting BCG primed animals intradermally or endobronchially with recombinant Ad85A resulted in similar peripheral blood mononuclear cell responses to PPD-B or antigen 85A, whereas specific immune responses were not readily detected in BAL because of a high background response in immunized animals. 56 Taken together, these reports suggest that locally initiated immune responses have an important role in the early control of Mtb infection after exposure, although definitive evidence for their role in mediating protection in humans has yet to be obtained. Nevertheless, it seems logical that a successful vaccination strategy should aim to induce protective pulmonary cellular responses that can rapidly respond to Mtb, as well as systemic immunity, such as that generated by parenteral BCG, which has a later effect on Mtb growth (Figure 1) . For optimal design of novel TB vaccine strategies, the immunological conditions and innate immune signaling pathways necessary for the generation and maintenance of both these types of cellular memory responses will need to be better understood.
LOCAL AND SYSTEMIC INNATE IMMUNITY
There is increasing evidence that appropriate innate immunity is essential for protection against TB in animal models. 17, [57] [58] [59] As well as inducing an antigen-specific response, parenteral BCG induces changes in gene expression in the lungs of mice more related to the innate immune system and tissue repair mechanisms than to adaptive immunity. 60 Furthermore, BCG induces a state of ''trained immunity'' in macrophages, persisting for several months and conferring increased nonspecific protection against other infections. In addition to general changes in innate immunity mediated by exposure to microbes, the many differences between pulmonary and extra-pulmonary innate mechanisms need to be considered. Alveolar macrophages express higher levels of Toll-like receptor-9 and lower surface Toll-like receptor-2 than autologous monocytes, suggestive of a tissue-specific immune recognition and signaling system that shapes the subsequent adaptive and inflammatory immune response in the lung. 63, 64 Lung-specific receptors for Mtb such as surfactant protein A have an important role in mediating local lung immune responses by downregulating Toll-like receptor-4 and initiating a suppressive immunoregulatory environment in response to infection. 65 These distinct aspects of the innate immune system are also evident in the cellular subsets of the lung. BAL of healthy individuals are predominantly composed of alveolar macrophages (90%) and a minority population of lymphocytes (5-10%) in comparison with peripheral blood in which neutrophils and lymphocytes predominate, with a minority monocyte population. 66 Recently, the importance of activating the correct innate pathways in order to induce protective local immunity in the lungs with a subunit vaccine, has been elegantly demonstrated. Both Ad85A and VSV85A delivered to the LRT induce powerful, largely CD8, local immune responses but while Ad85A is protective against Mtb, VSV85A is not. The two vaccines induce differing levels of interleukin-12 and type I interferon and this balance is critical for induction of protective or non-protective immunity. 67 These data are in agreement with earlier reports that different adjuvants applied to the lungs have markedly different effects on protection against Mtb. 22, 45, 57 Although alterations in innate immune function clearly have a major effect on protection, different vectors or formulations of the same antigen can also alter the specificity of the adaptive response, targeting it to more or less protective epitopes. [68] [69] [70] Thus, an effective pulmonary vaccine will depend both on the use of protective antigens and the delivery of appropriate signals by vaccine vectors or adjuvants to the innate immune system. Further experiments in primates and on human lung immunity are a priority in order to define optimal methods for harnessing human pulmonary responses against TB.
HARNESSING LOCAL AND SYSTEMIC IMMUNITY
For immunization against TB, the heterologous prime boost paradigm has received much attention because BCG provides useful protective efficacy in infants, and it is therefore an attractive strategy to try to boost this with subunit vaccines. 71 In addition, parenteral prime boost regimes have been shown in animal models to induce powerful T-cell immune responses to many different antigens. [72] [73] [74] [75] However, very few TB parenteral prime boost regimes induce significantly better protection than BCG alone 12, 13, 71, 76, 77 and those that do often involve repeated immunization, 12, 71, 78 a protocol that may be successful because it induces entry of immune cells into non-lymphoid tissues.
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For TB, it has been suggested that parenteral priming and mucosal boosting might have the advantage that local lung immunity would control pathogen growth in the lungs, whereas systemic immunity might control growth of organisms that escape to other tissues. In support of this, several studies have shown improved protection over BCG using parenteral BCG priming followed by respiratory mucosal boosting. 37, 67, 71, 79 It is further assumed that the efficacy of parenteral/mucosal prime boost regimes is due to the expansion of primed antigenspecific cells following boosting. However, simultaneous immunization of mice with the same vaccine by the parenteral and mucosal routes can be more protective than immunization by either route alone. Furthermore, parenteral and mucosal administration of two subunit vaccines containing different antigens, and therefore precluding a prime boost effect, can induce additive protection. 22 Thus, an important outcome of combining parenteral and mucosal immunization may be to induce lung T RM resident in the airway compartment, as well as T RM present in other lung tissue compartments and memory cells in lymphoid tissues. These may have three effects on TB. First, antigen-specific T RM cells in BAL together with innate immune cells inhibit early growth of Mtb, second T RM cells in other lung tissue compartments may inhibit further Mtb growth after a lag of 10-14 days. Finally, T cells from lymphoid tissue may be recruited to maintain containment in the lung or prevent dissemination or the growth of organisms after dissemination.
CONCLUSIONS Surprisingly, in spite of the widely held view that animal models for TB vaccine testing have little predictive value, in aggregate multiple models accurately predicted the outcome of the recent MVA85A trial, 2 as parenteral boosting with MVA85A alone after parenteral BCG priming, only showed a nonsignificant trend toward increased protection over BCG in two out of five animal experiments. [5] [6] [7] [8] [9] The predictive accuracy of the models in the case of MVA85A therefore encourages the view that effective vaccine strategies in animals may also be effective in humans.
Abundant evidence suggests that immunization via the respiratory tract with the reference standard TB vaccine, BCG, can be highly effective in protecting against pulmonary challenge in mice, 22 guinea pigs, 80 cattle 81 and primates 54 and it has been safely administered to humans by aerosol, 82 as have vaccines against influenza or measles viruses. 83 In mice, subunit vaccines have been shown to be protective after respiratory immunization [36] [37] [38] whereas in primates, subunit viral vectored vaccines administered by aerosol are immunogenic. 32, 55 There is therefore good evidence on which to base human clinical trials of TB vaccines administered by the respiratory route. Although in animal experiments it is important to immunize the LRT, in humans it remains to be determined whether this is equally so or URT immunization will suffice, but other more important issues remain to be resolved. No protection data for any TB vaccine administered by the respiratory route except BCG 54 has yet been reported in primates. But the mouse data indicate the crucial importance of delivering the correct signals to the lung innate system, 67 suggesting that success in primates and humans will be equally dependent on correct innate signaling as well as the specificity of the response.
Animal data indicate not only that respiratory immunization is highly effective but that it can be even more so when combined in either prime boost or simultaneous immunization regimes with parenteral immunization. 22, 67, 84 We argue above that this may be because both early and later acting protective mechanisms are recruited by these immunization regimes.
These considerations allow the following conclusions. In aggregate, multiple animal models may be more predictive of success or failure in humans than previously believed. Animal evidence strongly supports the value of clinical trials of vaccines, and in particular BCG, administered by the respiratory route. A much better understanding of respiratory innate and adaptive immunity in humans is urgently needed and may be gained from well-planned trials of respiratory vaccines associated with experimental studies of URT and LRT immunity. Combining parenteral and respiratory immunization is promising but more investigation is needed to optimize prime/boost or simultaneous immunization strategies for humans.
